REVIVE Prospective Registry Cohort Study

Starting soon

Conditions studied: Oropharyngeal Dysphagia

In brief

The main purpose of this registry is to collect observational, long-term safety and effectiveness data in participants who have received iltamiocel as part of the blinded portion of the REVIVE clinical study.

Key facts

Study ID

NCT07429890

Run by

University of California, Davis

People needed

31

Starts

2026-08-30

Expected to finish

2032-06-30

Last updated by the study team

2026-06-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants who have received iltamiocel as part of participation in the REVIVE clinical study for males and females with tongue dysphagia (TD) are eligible, provided the following criteria are fulfilled:
• Has completed the Month 24 visit in the REVIVE study.
• Has received iltamiocel as part of the blinded portion of the REVIVE study.
• Must be willing and able to comply with the study procedures, is able to understand all study requirements and must agree to read and sign the informed consent form prior to any study-related procedures.

You may not qualify if…

• The following criteria will exclude participants from participation:
• Has received placebo as part of the blinded portion of the REVIVE study.
• Unable or unwilling to provide informed consent.
• Not available for, or willing to comply with the follow-up evaluations as required by the protocol.

Where it is running

• UC Davis Medical Center — Sacramento, California, United States
• UC SanFrancisco Medical Center — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.